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In April 1947, during a smallpox outbreak in New York
City (NYC), >6 million people were vaccinated. To deter-
mine whether vaccination increased cardiac death, we
reviewed NYC death certificates for comparable periods in
1946, 1947, and 1948 (N = 81,529) and calculated adjust-
ed relative death rates for the postvaccination period. No
increases in cardiac deaths were observed. 
S
mallpox was successfully eradicated in 1980 after a
global vaccination campaign by the World Health
Organization. After the terrorist events of September and
October 2001, the U.S. government initiated a campaign to
immunize the American military and civilian first-respon-
ders in the event of an intentional release of the smallpox
virus (1). From December through April 2003, smallpox
vaccine was administered to 29,584 civilians and 365,000
military personnel nationwide (2,3). By March 28, four
nonfatal and three fatal myocardial infarctions (MIs) had
been reported. Whether these ischemic deaths were vac-
cine-associated or co-incidental is unclear. 
To ascertain whether cardiac deaths increased after a
large 1947 smallpox vaccination campaign in New York
City (NYC), we examined death certificates from a 4-month
period in 1947 as well as from comparable periods in 1946
and 1948. Key findings were published in an earlier article
(4). We provide full results and additional methodologic
detail here.
The Study
From April 4 through May 2, 1947, 6.35 million New
Yorkers were vaccinated with the NYC Board of Health
vaccinia strain (5). We used newspaper accounts and NYC
Department of Health records to estimate the number of
adults vaccinated on each of the 29 days (5). Since all of
the 2003 cardiac events occurred from 4 to 17 days after
vaccination, the 1947 vaccination numbers were divided
equally across the same 14-day period to calculate the per-
son-time at risk for potential cardiac death. On the basis of
these estimates, we identified the 2- and 4-week “peak”
risk periods in 1947.
We obtained all death certificates issued in NYC for the
4-month period between March and June, 1946–1948,
from the NYC Municipal Archive. Cause of death was
coded according to the International Classification of
Diseases, 5th Revision (ICD-5) (6). We abstracted the date
of death, age of decedent, and ICD-5–coded primary and
other cause of death into an electronic database. We
defined cause of death as “cardiac” if the ICD-5 codes for
either cause included pericarditis (090), acute endocarditis
(091), chronic endocarditis (092), myocardial disease
(093), coronary artery diseases (094), and other disease of
the heart (095). 
We compared daily death rates during the postvaccina-
tion risk periods with rates at other times during the study
period. We used Poisson regression, a generalized linear
model appropriate for analysis of discrete data, to model
counts of cardiac deaths (7). Counts were used instead of
rates, as NYC’s population remained relatively constant
during the study’s 3-year timeframe. We also adjusted for
temporal trends in the data: a long-term trend from 1946 to
1948 (defined by weeks since January 1, 1946) and a sea-
sonal trend between March and June (defined by days
since March 1 for any given year). Secular trends were
modeled with linear and quadratic terms. The main model
included all cardiac deaths as the outcome variable and a
dichotomous “exposure” variable indicating whether the
death occurred during the 2-week risk period. Additional
models examined subsets of cardiac disease and all-cause
death as outcomes, as well as adjusting for noncardiac
death volume. 
An a priori power analysis found that the model had
>90% power to detect a 5% increase in cardiac fatalities in
the at-risk period. While this power would be more than
sufficient to detect an excess of 2 deaths in 29,584 civilians
(approximately 400 deaths in the 1947 NYC population of
6,000,000), it would not be able to detect very small eleva-
tions in risk. 
At the height of the 1947 vaccination campaign, from
April 17 to April 21, 500,000 to 1 million people were vac-
cinated daily (Figure 1). The 2-week at-risk period in 1947
was estimated to be April 22 to May 5, which encom-
passed 84% of the projected at-risk person-time for
adverse cardiac complications. The 4-week period was
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 5, May 2004 917
1At the time of this study, Dr. Karpati was jointly affiliated with the
New York City Department of Health and Mental Hygiene and the
Centers for Disease Control and Prevention.
*New York City Department of Health and Mental Hygiene, New
York, New York, USA; and †Centers for Disease Control and
Prevention, Atlanta, Georgia, USAidentified as April 16 to May 13 and included 99% of the
at-risk person-time.
During the months under review in 1946–1948, 81,529
death certificates were recorded, including 519 (0.6%)
records with an illegible cause of death. Of the remaining
81,010 records, 48% had heart disease listed as a cause of
death. A total of 9,112 (11%) specifically referred to coro-
nary artery or atherosclerotic disease. The number of daily
deaths from heart disease in the months of March to June
of 1946, 1947, and 1948 ranged from 72 to 149, with an
increasing long-term trend and decreasing seasonal trend
(Figure 2). In the 2-week estimated risk period in 1947,
1,545 cardiac deaths occurred of 3,156 total deaths (aver-
age 110 deaths per day, range 91–119 deaths) (Table 1). 
In the main regression model (Table 2), no independent
association was found between cardiac deaths and the 2-
week estimated risk period. The findings remained non-
significant when the model was restricted to those 50 to 64
years of age and when adjustments for noncardiac deaths
were made (rate ratio 1.01; 95% confidence interval 0.95
to 1.06). Additional analyses examining different out-
comes (all deaths, atherosclerotic deaths, or deaths due to
myopericarditis) did not show any significant increase in
deaths, nor did expanding the estimated risk period to 4
weeks.
Conclusions
Our analysis found no significant increase in reported
cardiac deaths after the 1947 mass smallpox vaccination
campaign in NYC. The campaign was unique in terms of
the number of people vaccinated in one area in a short peri-
od. The high intensity and coverage of the vaccination
campaign permitted a focused cardiac death assessment. 
Recent reports of cardiac deaths after smallpox vacci-
nation have raised concerns regarding the safety of the cur-
rent vaccination initiative. The NYC Board of Health
vaccinia strain used today is the same as was used in 1947
(5). As described in our prior publication (4), vaccinia is a
DNA virus with limited antigenic variability (8), and anti-
genic shifts are unlikely. Regarding the vaccinated popula-
tion, major risk factors, such as smoking and hypertension,
were more widespread in 1947 than they are at present
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Figure 1. Adult vaccination doses
administered and estimated person-
time at risk for fatal cardiac adverse
effects, New York City, 1947.
Figure 2. Daily deaths from cardiac
causes, New York City, March to
June, 1946–1948.(9–11), and the death rate due to heart disease was nearly
three times higher (11). If, as the 2003 cardiac fatalities
suggest, cardiac risk factors increase vaccine-associated
death rates, we should have seen an even-greater cardiac
mortality risk in 1947.
Our analysis has some limitations. First, this analysis
was ecologic, and we had no information on the vaccina-
tion status of decedents. More than 80% of the NYC pop-
ulation was vaccinated within the 4-week period, however,
which minimizes the risk of faulty ecologic inference. The
campaign urged all New Yorkers to get vaccinated, irre-
spective of age, health, or pregnancy (5), and the likeli-
hood of systematic bias that would mask an association is
small. 
Second, death certificate information may have been
incomplete or inaccurate. We extracted ICD codes for
>99% of hardcopy death certificates, and missed codes
were unlikely to affect the findings of the study. We also
have no reason to believe that cardiac deaths were system-
atically misclassified in the peak risk exposure period as
compared with other times. ICD-5 heart disease codes and
later ICD revisions have been assessed to have a high com-
parability ratio, from 0.98 to 1.01 (6).
Third, assumptions pertaining to a Poisson distribution
may not be appropriate for these cardiac death data (11).
However, no biologically plausible concern existed for
underdispersion, and goodness-of-fit statistics suggested
adequate fit. Null findings of the study reduce concern for
overdispersion, which could have otherwise potentially
caused us to report an association that was not causal. 
Finally, although the survey had substantial statistical
power to detect small increases in cardiac deaths in the
estimated at-risk period, extremely small increases may
not have been detectable. In a large population, even small
elevations in risk will produce a sizable absolute number
of deaths. In light of this limitation, common to all obser-
vational studies, these findings should be interpreted in the
context of other study findings. 
Any one study will not likely be able to definitively rule
out a causal relationship between cardiac deaths among
recent vaccinees and the vaccine itself, but findings from
our study provide some reassurance that the current small-
pox vaccination program is unlikely to increase risk for
death from coronary disease. In 1947, the commissioner of
health of NYC reminded his peers, “Whenever a large-
scale vaccination program is undertaken, there is always
the possibility that there may be some unfortunate compli-
cations…. In New York City, there are thousands of people
who become ill, and about two hundred of them die every
day. Since practically every person in New York City had
a recent vaccination, it was inevitable that some of them
would become ill and would die. Vaccination does not stop
the normal course of events. Neither should vaccination be
blamed for a death from cerebral hemorrhage, nephritis, or
coronary occlusion (5).”
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Table 1. Death counts by cause of death and postvaccination exposure period 
Timeframe  All deaths  Cardiac deaths  Atherosclerotic deaths 
Mar–Jun 1946  26,256  12,340  2,861 
Mar–Jun 1947  27,484  13,352  3,075 
Mar–Jun 1948  27,774  13,458  3,175 
2-week exposure period  3,156  1,545  280 
Table 2. Rate ratio (RR) and 95% confidence interval (CI) of cardiac death rates comparing postvaccination to reference periods,
a New 
York City, March–June, 1946–1948 
Outcome  Postvaccination period  RR (95% CI) 
All cardiac deaths (ICD-5 090–095)  April 22–May 5  1.01 (0.96 to 1.07) 
50- to 64-year-olds only    1.05 (0.95 to 1.15) 
Atherosclerotic cardiac deaths (ICD-5 094)  April 22–May 5  1.06 (0.97 to 1.16) 
50- to 64-year-olds only    1.00 (0.86 to 1.15) 
Myopericarditis deaths (ICD-5 090, 093)  April 22–May 5  1.00 (0.94 to 1.07) 
All deaths  April 22–May 5  1.00 (0.97 to 1.04) 
All cardiac deaths (ICD-5 090–095)  April 16–May 13  0.99 (0.95 to 1.04) 
aAll models are adjusted for long-term temporal and seasonal trends. 
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